(E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one
• 英文别名: (E)-2'-hydroxy-2,4,4',5-tetramethoxychalcone；2'-hydroxy-2,4,4',5-tetramethoxychalcone
• 化学式: C₁₉H₂₀O₆
• 分子量: 344.364
• InChiKey: AXUGKAPKSQUOCO-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 7.0h， 以40%的产率得到7-Methoxy-2-(2,4,5-trimethoxy-phenyl)-chroman-4-one
  参考文献：
  名称：

  摘要：

  Purpose. Aromatase inhibitors are known to prevent the conversion of androgens to estrogens and play a significant role in the treatment of estrogen dependent diseases such as breast cancer. Some flavonoids have been reported as potent aromatase inhibitors: therefore. in an effort to develop novel anti breast cancer agents. B ring substituted flavanones with a 7-methoxy group on A ring were synthesized and tested to assess their ability to inhibit aromatase activity and to determine the optimal B ring substitution pattern.Methods. A series of flavanones was prepared by cyclisation of 2'-hydroxychalcones previously obtained by Claisen-Schmidt condensation and the aromatase inhibitory activity or these compounds was investigated using human placental microsomes and radiolabeled [1.2,6,7-H-3]-androstenedione as substrate.Results. Almost all flavanones exhibited inhibitory effect on the aromatase activity but their potency was dependent on their B ring subtitution pattern. Hydroxylation at position 3' and/or 4' enhanced the anti-aromatase activity thus, 3'.4'-dihydroxy-7-methoxyflavanone was found to he twice more potent than aminoglutethimide. the first aromatase inhibitor clinically used.Conclusions. These results indicated that these flavanones could be considered as potential anti breast cancer agents through the inhibition of aromatase activity and allowed us to select some of these Compounds as skeleton for the development of flavonoid structurally-related aromatase inhibitors.

  DOI：

  10.1023/a:1014490817731
• 作为产物：
  描述：

  丹皮酚 、 2,4,5-三甲氧基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以52%的产率得到(E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  新型异寡糖原蛋白衍生物的合成和评价，可作为淀粉样β聚集和5-脂氧合酶的潜在双重抑制剂

  摘要：

  合成了一系列新的异源寡糖原蛋白（ISL）衍生物，并将其评估为β-淀粉样蛋白（Aβ）聚集和5-脂氧合酶（5-LO）的双重抑制剂。发现所有这些合成化合物均能有效抑制Aβ（1-42）聚集，其IC 50值为2.2±1.5μM至23.8±2.0μM。这些衍生物还显示出对5-LO的抑制活性，其IC 50值范围为6.1±0.1μM至35.9±0.3μM。研究了它们的结构-活性关系（SAR）和抑制机理。这项研究为进一步开发ISL衍生物作为阿尔茨海默氏病（AD）的多功能药物提供了潜在的重要信息。

  DOI：

  10.1016/j.ejmech.2013.05.015

文献信息

• Novel Chalcone Derivatives With Antimitotic Activity
  申请人：Boumendjel Ahcene

  公开号：US20090182058A1

  公开（公告）日：2009-07-16

  The present invention relates to novel chalcone derivatives of formula (I): wherein X, Y, Z, W, RI, R2, R3, R4 and R5 are as defined, said derivatives having antimitotic activity, as well as to pharmaceutical compositions containing such compounds and to their use for making drugs.

  本发明涉及具有抗有丝分裂活性的新型葵花素衍生物的公式(I)：其中X、Y、Z、W、RI、R2、R3、R4和R5如定义所述，以及含有这种化合物的药物组合物，以及其用于制备药物的用途。
• Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure–Activity Relationship
  作者：Ahcène Boumendjel、Julien Boccard、Pierre-Alain Carrupt、Edwige Nicolle、Madeleine Blanc、Annabelle Geze、Luc Choisnard、Denis Wouessidjewe、Eva-Laure Matera、Charles Dumontet

  DOI：10.1021/jm0708331

  日期：2008.4.1

  A series of 59 chalcones was prepared and evaluated for the antimitotic effect against K562 leukemia cells. The most active chalcones were evaluated for their antiproliferative activity against a panel of I I human and murine cell cancer lines. We found that three chalcones were of great interest as potential antimitotic drugs. In vivo safety studies conducted on one of the most active chalcones revealed that the compound was safe, allowing further in vivo antitumor evaluation.
• DERIVES DE CHALCONE A ACTIVITE ANTIMITOTIQUE
  申请人：UNIVERSITE CLAUDE BERNARD - LYON 1

  公开号：EP1976818A2

  公开（公告）日：2008-10-08
• [EN] NOVEL CHALCONE DERIVATIVES WITH ANTIMITOTIC ACTIVITY<br/>[FR] NOUVEAUX DERIVES DE CHALCONE A ACTIVITE ANTIMITOTIQUE
  申请人：UNIV CLAUDE BERNARD LYON

  公开号：WO2007083060A2

  公开（公告）日：2007-07-26

  [EN] The present invention relates to novel chalcone derivatives of formula (I): in which X, Y, Z, W, R1, R2, R3, R4 and R5 are as defined, wherein said derivatives have antimitotic activity, and also to the pharmaceutical compositions containing such compounds and to the use thereof for the manufacture of medicaments.
  [FR] La présente invention concerne de nouveaux dérivés de chalcone de formule (I) : dans laquelle X, Y, Z, W, R1, R2, R3 R4 et R5 sont tels que définis, lesdits dérivés présentant une activité antimitotique, ainsi que les compositions pharmaceutiques contenant de tels composés et leur utilisation pour la fabrication de médicaments.
• [EN] ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF<br/>[FR] CO-LIGANDS DES RÉCEPTEURS DES OESTROGÈNES ALPHA ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2017132135A1

  公开（公告）日：2017-08-03

  Provided herein is a coligand for the estrogen receptor (ER) α subunit, and methods of use thereof in treating conditions associated with ER signaling in an individual. The present ERα coligand may be a cell type-selective, allosteric modulator of ERα signaling. The ERα coligand, when administered to an individual, may modulate ER agonist-dependent signaling in a tissue-selective manner.